Neptune Technologies & Bioressources Confirms Dividend of Acasti Rights

Neptune Technologies & Bioressources NEPT announces that, following the announcement by Acasti Pharma, a subsidiary of Neptune, of a rights offering to its shareholders of record date July 5, 2011 and Neptune's announcement that the rights it would receive from Acasti would be transferred to its own shareholders at the Record Date in payment of a dividend on its common shares, Neptune announces that is has received on the date hereof a total of 38,617,733 rights pursuant to Acasti's rights offering. Accordingly, Neptune confirms that the value of the dividend declared on its common shares is of $0.030421697 CDN per common share and that this dividend is paid by the transfer to Neptune's shareholder at the Record Date of 0.787 of an Acasti Right per common share of Neptune. For more information concerning Acasti's rights offering and Neptune's dividend, see Acasti and Neptune's joint press release of June 16, 2011 and the rights offering circular filed by Acasti on SEDAR at www.sedar.com.